ABSTRACT:

The inhibitory effects of six commonly used calcium channel blockers on three major cytochrome P-450 activities were examined and characterized in human liver microsomes. All six compounds reversibly inhibited CYP2D6 (bufuralol 1′-hydroxylation) and CYP2C9 (tolbutamide methyl hydroxylation) activities. The IC_{50} values for the inhibition of CYP2D6 and CYP2C9 for nicardipine were 3 to 9 μM, whereas those for all others ranged from 14 to >150 μM. Except for nifedipine, all calcium channel blockers showed increased inhibitory potency toward CYP3A activities (testosterone 6β-hydroxylation and midazolam 1′-hydroxylation) after 30-min preincubation with NADPH. IC_{50} values for the inhibition of testosterone 6β-hydroxylation and midazolam 1′-hydroxylation activities in the NADPH-preincubation experiment for nicardipine (1 μM), verapamil (2 μM), and diltiazem (5 μM) were within 10-fold, whereas those for amiodipine (5 μM) and felodipine (13 μM) were >200-fold of their respective plasma concentrations reported after therapeutic doses. Similar results also were obtained based on midazolam 1′-hydroxylase activity. Unlike the observations with mibebradil, a potent irreversible inhibitor of CYP3A, the NADPH-dependent inhibition of CYP3A activity by nicardipine and verapamil was completely reversible on dialysis, whereas that by diltiazem was partially restored (80%). Additional experiments revealed that nicardipine, verapamil, and diltiazem formed cytochrome P-450-iron (II)-metabolite complex in both human liver microsomes and recombinant CYP3A4. Nicardipine yielded a higher extent of complex formation (~30% at 100 μM), and was a much faster-acting inhibitor (maximal inhibition rate constant ~2 min⁻¹) as compared with verapamil and diltiazem. These present findings that the CYP3A inhibition caused by nicardipine, verapamil, and diltiazem is, at least in part, quasi-irreversible provide a rational basis for pharmacokinetically significant interactions reported when they were coadministered with agents that are cleared primarily by CYP3A-mediated pathways.

Calcium channel blockers (CCBs) have been used widely for the treatment of hypertension, angina pectoris, and other cardiovascular diseases since first introduced in the 1960s. With such widespread use, there have been a number of reports on significant pharmacokinetic and pharmacodynamic drug interactions associated with CCBs (Hunt et al., 1989; Kirch et al., 1990; Schlanz et al., 1991; Rosenthal and Ezra, 1995; Lamberg et al., 1998). Most recently, numerous cases have been reported in patients receiving mibebradil, a newly introduced CCB, which ultimately motivated the voluntary withdrawal of the compound from the market (Welker et al., 1998). Inhibition of cytochrome P-450 (P-450) activities by CCBs has been suggested as one of possible explanations for such interactions. However, little has been reported in the literature on inhibitory effects of CCBs on human P-450s’ activities other than those of CYP3A. Close examination of the data available on CYP3A indicated that, except for mibebradil, CCBs are not very potent P-450 inhibitors. Values for IC_{50} or K_{i} for inhibition of CYP3A activities in human liver microsomes ranged from ~10 μM for nicardipine to 100 μM for diltiazem (Tjia et al., 1989; Pichard et al., 1990; Wrighton and Ring, 1994; Zhao and Ishizaki, 1997). These values are over 100-fold greater than typical plasma concentrations of CCBs reported after clinical doses (Kelly and O’Malley, 1992). Recently, diltiazem has been shown to be a quasi-irreversible inhibitor of CYP3A both in vitro and in vivo in rats (Bensoussan et al., 1995). Although these results have not been confirmed with human liver microsomes, they appeared consistent with several significant drug interactions reported for diltiazem in vivo (Lin and Lu, 1998). To date, there have been limited data on mechanisms of CYP3A inhibition by other CCBs in animals or humans.

Chemically, CCBs (Fig. 1) are classified into three classes, benzothiazepines (e.g., diltiazem), dihydropyridines (e.g., amiodipine, felodipine, nicardipine, and nifedipine), and phenylalkylamines (e.g., verapamil). Like diltiazem, most of these CCBs contain an amine functional group and undergo N-dealkylation; both features are common for metabolic intermediate (MI) complexing agents such as diltiazem and several other amine-containing compounds (Pershing and Franklin, 1982; Bensoussan et al., 1995). However, possible formation of such a complex has not been reported for any of the amine-containing phenylalkylamines and dihydropyridines.

In this study, we examined and characterized the in vitro inhibition profiles of six commonly used CCBs (amiodipine, diltiazem, felodipine, nicardipine, nifedipine, and verapamil) on three major P-450 isozymes (CYP3A, CYP2D6, and CYP2C9) in human liver microsomes. Mibebradil, the CCB recently shown to be a potent mechanism-based inhibitor of CYP3A (Prueksaritanont et al., 1999), also was included in the study for comparison. In addition, the ability of
CYP2D6 (quinidine), and CYP2C9 (sulfaphenazole) were included as positive controls. Microsomes were preincubated with CCBs for 30 min at 37°C, either in the absence or presence of NADPH (Fig. 2, A and B; Table 1). Both ketoconazole and TAO produced inhibitory profiles consistent with their mechanisms of inhibition. The potent reversible inhibitor ketoconazole did not show an increased inhibitory effect after preincubation with NADPH (Table 1). In fact, a decreased inhibition was observed (Fig. 2B, Table 1). This was consistent with the fact that ketoconazole is a substrate for CYP3A. Also as expected, the quasi-irreversible inhibitor TAO showed increased inhibitory potency when preincubated in the presence of NADPH (Fig. 2A and B; Table 1). In addition, IC50 values obtained in the present study for both ketoconazole and TAO agreed well with those reported previously (Wrighton and Ring, 1994; Eagling et al., 1998; McKillop et al., 1998).

Among the six CCBs examined and after preincubation without NADPH, nicardipine was the most potent inhibitor (IC50 = 1.7 μM) of testosterone 6β-hydroxylation activity. All other CCBs showed comparable inhibitory potencies, with IC50 values ranging from ~20 to ~80 μM (Fig. 2A, Table 1). The IC50 values of verapamil, diltiazem, and nifedipine for 6β-testosterone hydroxylase were comparable to those reported earlier using cyclosporin, quinine, or midazolam as a CYP3A probe (Tjia et al., 1989; Pichard et al., 1990; Wrighton and Ring, 1994; Sutton et al., 1997; Zhao and Ishizaki, 1997). With the exception of nifedipine, the inhibition effects of all CCBs were comparable, with IC50 values ranging from ~20 to ~80 μM (Fig. 2A, Table 1). In the preincubation experiment with NADPH, nicardipine also was the most potent inhibitor (IC50 = ~0.9 μM), whereas nifedipine was the least potent inhibitor (IC50 = ~30 μM). Under similar conditions, the IC50 value for mibefradil was 0.3 μM (Prueksaritanont et al., 1999).

The inhibitory profiles of these CCBs and the known inhibitors on midazolam 1'-hydroxylase activity, another commonly used CYP3A marker, were very similar to those of testosterone 6β-hydroxylase activity (Table 1). In most cases, values for IC50 obtained for the two probes were very similar.
markers were within 2-fold of each other (Table 1). This similarity in the IC50 values, which were obtained at their Km values, were consistent with the fact that both markers are substrates for CYP3A. As was observed with testosterone 6β-hydroxylation, nicardipine also was more potent than the other CCBs tested, but was less potent than mibefradil in inhibiting midazolam 1β-hydroxylation.

Inhibitory Effects of CCBs on CYP2D6 Activity. Unlike the observations on CYP3A activity, none of the CCBs examined showed increases in inhibitory potencies or decreases in IC50 values toward CYP2D6 activity (bufuralol 1β-hydroxylase) after preincubation with NADPH (Table 2). Among the CCBs studied, the most and the least potent inhibitor were nicardipine (IC50 = 2.8 μM) and diltiazem (IC50 > 150 μM), respectively (Table 2). The inhibitory potencies of verapamil, amlodipine, felodipine, and nifedipine were comparable, with IC50 values ranging between 40 and 70 μM. The results obtained with nicardipine were similar to those reported previously (Fonne-Pfister and Meyer, 1988). Under the present conditions, the IC50 value (0.06 μM) of quinidine, a known CYP2D6-selective inhibitor, on CYP2D6 activity also was comparable to that reported earlier (Haldiday et al., 1995).

Inhibitory Effects of CCBs on CYP2C9 Activity. Similar to the above findings on CYP2D6 activity, inhibitory effects of the CCBs on CYP2C9 activity (tolbutamide methyl hydroxylase) were not increased by preincubation in the presence of NADPH (Table 3). In either experiment, nicardipine was the most potent inhibitor (IC50 = 7–9 μM), whereas verapamil and diltiazem were much less potent inhibitors than any CCBs tested as indicated by their IC50 values of >140 μM (Table 3). In agreement with previous reports (Eagling et al., 1998; von Molk et al., 1998), the known CYP2C9-selective inhibitor sulfaphenazole yielded an IC50 value of 0.5 μM.

Characterization of CYP3A Inhibition. To characterize the apparent NADPH-dependent inhibition observed on CYP3A activity, nicardipine, verapamil, and diltiazem were chosen for additional studies. As shown in Fig. 3, the inhibition of testosterone 6β-hydroxylation by nicardipine, verapamil, and diltiazem was both time- and
concentration-dependent. Nicardipine was a fast-acting inhibitor, whereas diltiazem was a much slower inhibitor. Values for the maximal inhibition rate constant and apparent $K_i$ of nicardipine, verapamil, and diltiazem were estimated, based on reciprocal plots of the initial inhibition rate constant and CCB concentration, to be 2, 0.03, and 0.01 min$^{-1}$ and 0.6, 0.5, and 0.5 μM, respectively.

**Reversibility of CYP3A Inhibition.** Reversibility of the inhibition of CYP3A activity by nicardipine, verapamil, and diltiazem was examined by dialysis. As expected, the activity of CYP3A that was inhibited by all of the inhibitors examined after preincubation without NADPH was virtually restored by dialysis (Table 4). In the experiment with NADPH present during preincubation, CYP3A activity inhibited by nicardipine and verapamil also was fully recovered after dialysis (Table 4). However, dialysis only partially (~80%) restored the inhibited CYP3A activity by diltiazem (Table 4). In a parallel experiment with mibefradil and ethynylestradiol, both potent irreversible inhibitors of CYP3A (Guengerich, 1988; Pruksartanont et al., 1999), only 14 to 31% of the control activity was recovered after dialysis (Table 4).

**Formation of P-450-Metabolite Complex.** In vitro studies were further conducted to investigate whether the NADPH-dependent inhibition of CYP3A activity by nicardipine, verapamil, and diltiazem was via the formation of MI complex. The three CCBs all contain an amine functional group, formed P-450-iron (II)-metabolite complex, as evident by a Soret peak at around 455 nm (Buening and Franklin, 1976; Pershing and Franklin, 1982; Bensoussan et al., 1995) when incubated with human liver microsomes in the presence of NADPH (Fig. 4, A–C). Under the conditions used (which yielded ~40% complex formation for TAO, data not shown), the extent of complex formation was estimated to be ~30, 20, and ~6% for nicardipine, diltiazem, and verapamil, respectively. Similar results also were observed with recombinant CYP3A4 (Fig. 4, A–C), but not CYP2D6 or CYP2C9 (data not shown). Addition of ferricyanide reduced absorbance at the maxima, consistent with dissociation of the complex and regeneration of P-450-iron (III) (Fig. 4, A–C). These results are in agreement with the aforementioned NADPH-dependent inhibition of nicardipine, diltiazem, and verapamil on CYP3A, and not CYP2D6 or CYP2C9 activity, and supported that this inhibition was due, in part, to the complex formation between their metabolites and CYP3A.

**Discussion**

Mechanisms of CYP inhibition of a compound can be divided into three categories: reversible, quasi-reversible, and irreversible (Lin and Lu, 1998). Quasi-reversible and irreversible inhibitors require at least one cycle of the CYP catalytic process, and are thus signified by both NADPH- and time-dependent inhibition. Experimentally, mechanisms of inhibition of inhibitors could be assessed initially by comparing their inhibitory effects obtained in the presence and absence of NADPH during a preincubation period. In the present study, the IC$_{50}$ values obtained for all CCBs tested on CYP2D6 or CYP2C9 activity in the presence of NADPH were not lower than those observed in the absence of NADPH during preincubation. This NADPH-independent inhibition suggests that all six CCBs are not quasi-irreversible or irreversible, but rather reversible inhibitors for these isozymes. In contrast, except for nifedipine, all CCBs tested showed increased inhibitory potencies (up to 16-fold) toward CYP3A activities when preincubated in the presence of NADPH. The results suggest that these CCBs may be converted, at least in part, to reactive intermediates or products that contribute to the overall inhibition, either reversible, quasi-irreversible, or irreversible, of CYP3A activities.

To characterize this apparent NADPH-dependent inhibition, nicardipine, verapamil, and diltiazem, representatives of dihydropyridines, phenylalkylamines, and benzothiazepines, respectively, were selected for additional studies. Based on the finding that NADPH-dependent inhibition was completely reversible on dialysis (Table 4), both nicardipine and verapamil are not irreversible inactivators for human CYP3A. The finding of ~20% irreversible inhibition on dialysis after preincubation of diltiazem with NADPH (Table 4) suggests that diltiazem might act in part as an irreversible inhibitor of CYP3A. A possibility also exists that highly potent metabolite(s) of diltiazem, such as N-desmethyl diltiazem and N$_2$-didesmethyl diltiazem (Sutton et al., 1997), due possibly to tight binding, could remain in the incubation mixture after the 16-h dialysis period.

Subsequent studies showed that nicardipine, verapamil, and diltiazem were able to form P-450-iron (II)-metabolite complex in human liver microsomes and in recombinant human CYP3A4, indicating that they are quasi-irreversible inhibitors of CYP3A4. These results were not unexpected considering that N-demethylated metabolites, all shown to be mediated by CYP3A (Kroemer et al., 1993; Sutton et al., 1997; Fukunaga et al., 1998), have been observed after administration of the three CCBs, and that N-dealkylation of a secondary or tertiary amine has been suggested as the first step leading to formation of P-450-iron (II)-metabolite complex. The smaller extent of the complex formation observed with verapamil (~6%) as compared with that obtained with nicardipine (30%) or diltiazem (20%) suggests that the MI complex formation contributed relatively less to the overall NADPH-dependent inhibition for verapamil than for nicardipine or diltiazem. Considering that verapamil exhibited lower IC$_{50}$ values (Table 1) and higher maximal inhibition rate constant/K$_i$ ratio than diltiazem, the relatively low level of MI complex observed for verapamil suggests that metabolite(s) of verapamil might also be potent, but reversible inhibitor(s). It is also interesting to point out that the
metabolite complexes observed with these CCBs were relatively unstable on dialysis because virtually complete restoration of testosterone 6β-hydroxylase activity was observed after dialysis in the case of nicardipine and verapamil (Table 4). A similar observation was also obtained in our laboratory with TAO, a known P-450-metabolite complex-forming agent (Table 4). It is presently unclear whether the P-450-iron (II)-metabolite complex formed by diltiazem was more stable than that of complexes formed by nicardipine, verapamil, or TAO.

Based on the above observations and considering typical plasma concentrations of ~0.1 to 0.4 μM for nicardipine, verapamil, diltiazem, and nifedipine, and of ~5 to 50 nM for amlodipine and felodipine (Kelly and O’Malley, 1992), all CCBs tested, with the exception of nicardipine, could be considered as weak reversible inhibitors for CYP2D6 and CYP2C9. Significant degree of metabolic inhibition on CYP2D6 and CYP2C9 activities may not be expected after a therapeutic dose of verapamil, diltiazem, nifedipine, amlodipine, or felodipine. However, the present study suggested, based on their IC50 values (0.9–5 μM) obtained in the presence of NADPH preincubation relative to their therapeutic concentrations (0.1–0.4 μM), that nicardipine, verapamil, and diltiazem are relatively potent inhibitors of CYP3A in humans. Inhibition of CYP3A activities likely contributed, at least in part, to the previously observed decreased clearances or increased plasma concentrations of CYP3A substrates after concomitant administration with nicardipine, diltiazem, and verapamil (Kirch et al., 1990; Schlanz et al., 1991; Rosenthal and Ezra, 1995; Azie et al., 1998; Kantola et al., 1998; Lamberg et al., 1998). The above conclusion is additionally supported by the present finding that the three CCBs are quasi-irreversible inhibitors of CYP3A, eliciting inhibitory effects, in part, via MI complex. In vivo, such a complex is known to be so stable that the CYP involved in the complex formation would be unavailable for drug metabolism. As a result, the inhibitory effects of quasi-reversible inhibitors are more prominent after multiple dosing and last longer than those of reversible inhibitors (Murray and Reidy, 1990; Lin and Lu, 1998). Consistent with these, there have been several cases of significant interactions noted after repeated doses of nicardipine, verapamil, or diltiazem with CYP3A substrates as compared with after other CCBs (Kirch et al., 1990; Schlanz et al., 1991; Rosenthal and Ezra, 1995; Azie et al., 1998; Kantola et al., 1998; Lamberg et al., 1998). The relatively fewer cases of pharmacokinetic interactions reported for felodipine and amlodipine also appeared to be consistent with the present finding that their IC50 values obtained in the presence of NADPH were >200-fold higher than reported plasma concentrations after a therapeutic dose. Noteworthy, the potent and irreversible CYP3A inhibitor mibefradil, which was recently withdrawn from the market due to drug-interaction potential, exhibited lower IC50 value (0.3 μM) relative to its therapeutic concentrations (0.5–1 μM) than all six CCBs studied (Prueksaritanont et al., 1999).

To conclude, the present results revealed that among six CCBs tested, only nifedipine was a reversible inhibitor of CYP3A, CYP2D6, and CYP2C9. All other CCBs reversibly inhibited CYP2D6 and CYP2C9, but not CYP3A activities. Based on ratios between IC50 values obtained in the presence of NADPH during preincubation and the respective therapeutic concentrations, nicardipine, verapamil, and diltiazem are relatively potent inhibitors of CYP3A. In addition, the three CCBs inhibited CYP3A activities, at least in part, through the formation of MI complex, and thus are classified as quasi-reversible inhibitors. The results provide a rational basis for significant pharmacokinetic interactions reported between these CCBs and P-450 substrates, and support the notion that an understanding of the underlying interactions and overall metabolic stability of these CCBs is an important aspect in the development of new drugs.
mechanism of inhibition is important to provide valuable insights into drug-drug interactions observed in vivo (Lin and Lu, 1998).

Acknowledgments. We thank Dr. Anthony Y. H. Lu of Rutgers University for a critical review of the manuscript and Dr. Magang Shou for providing insect microsomes expressed with human CYP3A4 and NADPH-dependent reductase.

References


